Reply to comment on Pepe et al.: Somatostatin receptor SPECT

Giovanna Pepe · Arturo Chiti

Received: 16 October 2012 / Accepted: 17 October 2012 / Published online: 18 November 2012
© Springer-Verlag Berlin Heidelberg 2012

Dear Sir,

We appreciate the interest of Dr. Hubalewska-Dydejczyk and colleagues [1] in our article “Somatostatin receptor SPECT” [2]. We regret the disappointment resulting from a misunderstanding about our statement regarding the registration status of ^{99m}Tc -EDDA/HYNIC-TOC. We would like to underline that in our review, referring to this tracer, we declared that “interestingly it is currently being offered as a routine product by POLATOM (Warsaw, Poland)”, and we are happy, following the comment of Dr. Hubalewska-Dydejczyk et al., to make clear that this radiopharmaceutical has been registered in Poland since 2004 and, as we read in the article by Maecke and Reubi, is

actually “commercially available in some European countries” [3].

References

1. Hubalewska-Dydejczyk A, Sowa-Staszczak A, Tomaszuk M. Comment on Pepe et al.: Somatostatin receptor SPECT. *Eur J Nucl Med Mol Imaging*. 2012;39:1656–7.
2. Pepe G, Moncayo R, Bombardieri E, Chiti A. Somatostatin receptor SPECT. *Eur J Nucl Med Mol Imaging*. 2012;39:S41–51.
3. Maecke HR, Reubi JC. Somatostatin receptors as targets for nuclear medicine imaging and radionuclide treatment. *J Nucl Med*. 2011;52(6):841–4.

G. Pepe (✉) · A. Chiti
Nuclear Medicine, IRCCS Humanitas,
Milan, Italy
e-mail: giovanna.pepe@humanitas.it